TY - JOUR
T1 - Novel Insights into Membrane Targeting of B Cell Lymphoma
AU - de Winde, Charlotte M.
AU - Elfrink, Suraya
AU - van Spriel, Annemiek B.
PY - 2017/6
Y1 - 2017/6
N2 - Standard therapy of patients with B cell non-Hodgkin lymphoma (B-NHL) predominantly consists of chemotherapy combined with anti-CD20 (e.g., rituximab) immunotherapy. However, relapse of aggressive B-NHL occurs frequently, and this may coincide with therapy resistance. This demonstrates the urgent need for exploring new lymphoma-targeted therapies. We review here recent insights in the pathophysiology of B-NHL and discuss CD20 and three alternative membrane targets (B cell receptor, immune checkpoints PD-1/PD-L1, tetraspanin CD37) that are currently in the spotlight for B-NHL treatment. Furthermore, we present a novel concept in which the plasma membrane organization of the lymphoma B cell determines the efficacy of membrane-targeted therapies, and this has consequences for treatment application and clinical outcome in patients with B cell lymphoma.
AB - Standard therapy of patients with B cell non-Hodgkin lymphoma (B-NHL) predominantly consists of chemotherapy combined with anti-CD20 (e.g., rituximab) immunotherapy. However, relapse of aggressive B-NHL occurs frequently, and this may coincide with therapy resistance. This demonstrates the urgent need for exploring new lymphoma-targeted therapies. We review here recent insights in the pathophysiology of B-NHL and discuss CD20 and three alternative membrane targets (B cell receptor, immune checkpoints PD-1/PD-L1, tetraspanin CD37) that are currently in the spotlight for B-NHL treatment. Furthermore, we present a novel concept in which the plasma membrane organization of the lymphoma B cell determines the efficacy of membrane-targeted therapies, and this has consequences for treatment application and clinical outcome in patients with B cell lymphoma.
KW - B cell
KW - immunotherapy
KW - membrane organization
KW - membrane target
KW - non-Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85019230722&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.trecan.2017.04.006
DO - https://doi.org/10.1016/j.trecan.2017.04.006
M3 - Review article
C2 - 28718418
SN - 2405-8033
VL - 3
SP - 442
EP - 453
JO - Trends in Cancer
JF - Trends in Cancer
IS - 6
ER -